Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Instil Bio Inc TIL

Instil Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies. The Company seeks to in-license/acquire and develop novel therapeutic candidates in diseases with significant unmet medical need. Its first such program is an engineered tumor infiltrating lymphocyte (TIL), cell therapy for the treatment of cancer. It is engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor (CoStAR), platform. The Company's lead CoStAR-TIL product candidate, ITIL-306, expresses a CoStAR molecule designed to recognize folate receptor alpha (Fra), a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC and renal cancer. CAR-T and TCR-T therapies are cell products composed of T cells that have been genetically engineered to recognize a specific cancer-related antigen on the surface of tumor cells.


NDAQ:TIL - Post by User

Bullboard Posts
Post by wordlesson May 06, 2013 12:26pm
297 Views
Post# 21343278

How's this for a vote of confidence

How's this for a vote of confidence

Bill Sherrif bought 2,400,000 shares fo the recent PP

 

 

Latest 10 SEDI filings (by transaction date) for AMB within the last 6 months [?]
Amended Filing

 

  As of 11:59pm ET May 5th, 2013
Filing
Date
Transaction
Date
Insider Name Ownership
Type
Securities Nature of transaction # or value acquired or disposed of Price
May 3/13 May 3/13 Sheriff, William Morris Direct Ownership Common Shares 10 - Acquisition in the public market 50,000 $0.215
Mar 27/13 Mar 25/13 Sheriff, William Morris Direct Ownership Common Shares 16 - Acquisition under a prospectus exemption 2,400,000 $0.240
Mar 26/13 Mar 25/13 Lee-Sheriff, Janet Direct Ownership Common Shares 16 - Acquisition under a prospectus exemption 40,000 $0.240
Mar 26/13 Mar 25/13 Rayment, Barry Donald Direct Ownership Common Shares 16 - Acquisition under a prospectus exemption 50,000 $0.240
Mar 26/13 Mar 25/13 Skimming, Thomas Direct Ownership Common Shares 16 - Acquisition under a prospectus exemption 100,000 $0.240
Mar 26/13 Mar 25/13 Zink, Paul Harper Direct Ownership Common Shares 16 - Acquisition under a prospectus exemption 100,000 $0.240
Mar 26/13 Mar 25/13 Leybold, Timothy Paul Direct Ownership Common Shares 16 - Acquisition under a prospectus exemption 40,000 $0.240
Mar 27/13 Mar 18/13 Sheriff, William Morris Direct Ownership Common Shares 11 - Disposition carried out privately -2,100,000 $0.240
Mar 12/13 Mar 12/13 Rayment, Barry Donald Direct Ownership Warrants 55 - Expiration of warrants -11,687 $0.600
Mar 12/13 Mar 4/13 Zink, Paul Harper Direct Ownership Options 50 - Grant of options 750,000 $0.300

 

Bullboard Posts